A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

ClinicalTrials.gov ID: NCT07015242

Public ClinicalTrials.gov record NCT07015242. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

Study identification

NCT ID: NCT07015242
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Enrollment: 65 participants

Conditions and interventions

Conditions

Lymphoma

Interventions

Rituximab Drug
Methotrexate Drug
Procarbazine Drug
Temozolomide Drug
Liso-cel Biological
Fludarabine Drug
Cyclophosphamide Drug
Calcium folinate Drug

Drug · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 5, 2025
Primary completion: Jan 8, 2028
Completion: Dec 9, 2028
Last update posted: Jul 1, 2026

2025 – 2028

United States locations

U.S. sites: 14
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
University Of Colorado	Aurora	Colorado	80045	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612-9416	Recruiting
Robert H. Lurie Comprehensive Cancer Center of Northwestern University	Chicago	Illinois	60611	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Washington University School of Medicine in St. Louis	St Louis	Missouri	63110-1010	Recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08901	Recruiting
Roswell Park Comprehensive Cancer Center	Buffalo	New York	14263	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10021	Recruiting
Cleveland Clinic	Cleveland	Ohio	44195	Recruiting
The Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43202-2224	Recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
Sarah Cannon Research Institute Oncology Partners	Nashville	Tennessee	37203	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07015242, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 1, 2026 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07015242 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →